Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propagermanium in Diabetic Kidney Disease (ACTION)
NCT03627715Phase 2Completed
- Sponsor
- Dimerix
- Start
- Nov 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of repagermanium in diabetic kidney disease (DKD) (2 arms), sponsored by Dimerix. Primary endpoint: Change in Albumin/Creatinine Ratio with Adjunct use of Propagermanium Compared to Placebo at 12 weeks. Started Nov 2018; status: completed.
02
Drugs
repagermanium
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT03627715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627715.